AbbVie Inc header image

AbbVie Inc

ABBV

Equity

ISIN null / Valor 20145667

New York Stock Exchange, Inc (2026-09-04)

USD 256.46-1.44%

AbbVie Inc
UMushroom community rating:

4.50 2 votes No rating yet

NegativeNeutralPositive

About company

AbbVie Inc. is a global biopharmaceutical company dedicated to researching, developing, and marketing innovative medicines and medical solutions. With a workforce of over 50,000 employees across more than 70 countries, AbbVie focuses on addressing complex health challenges and improving the quality of life for people around the world. The company has a significant presence in research and development (R&D) and manufacturing, with facilities in approximately 20 countries. AbbVie's portfolio includes treatments for over 75 conditions, and its products reach around 50 million people annually in 175 countries. The company also emphasizes collaboration, maintaining over 250 partnerships with biotech firms, universities, nonprofits, and government organizations to advance scientific discovery. AbbVie's commitment to innovation is underscored by its development pipeline, which includes more than 80 compounds, devices, or indications.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

20.4%1Y

73.0%3Y

130%5Y

Performance

26.3%1Y

25.0%3Y

23.8%5Y

Volatility

453195 M

Market cap (USD)

4,729,801

Daily traded volume (Shares)

177.34 / 175.6

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.50

2 votes

Performance:

5.00

Innovation:

4.50

Society:

3.50

Nature:

3.50

Lou Charlotte Wehrli

Switzerland, 15 May 2024

Interesting Stock and business model. Since people are obsessed with health and beauty, there is potential there.

Luba Schoenig

Switzerland, 15 May 2024

AbbVie Inc. has demonstrated robust financial health in its first-quarter 2024 results.

EQUITIES OF THE SAME SECTOR

Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB Valor: 2676862

Annual Return

-50%0%+50%

Risk level

110

-1.13%SEK 454.80

Indivior PLC

Indivior PLC Valor: 121550831

Annual Return

-50%0%+50%

Risk level

110

0.35%GBP 25.85

Vitrolife AB

Vitrolife AB Valor: 41707777

Annual Return

-50%0%+50%

Risk level

110

-1.50%SEK 95.00

Camurus AB

Camurus AB Valor: 30510553

Annual Return

-50%0%+50%

Risk level

110

-2.17%SEK 587.00

DBV Technologies SA

DBV Technologies SA Valor: 2857349

Annual Return

-50%0%+50%

Risk level

110

-2.54%EUR 2.31

CVS Group PLC

CVS Group PLC Valor: 3457960

Annual Return

-50%0%+50%

Risk level

110

0.00%GBP 13.16

International Flavors & Fragrances Inc

International Flavors & Fragrances Inc Valor: 941876

Annual Return

-50%0%+50%

Risk level

110

-0.13%USD 86.35

Neumora Therapeutics Inc

Neumora Therapeutics Inc Valor: 129329732

Annual Return

-50%0%+50%

Risk level

110

-2.96%USD 1.31

Savaria Corp

Savaria Corp Valor: 1385257

Annual Return

-50%0%+50%

Risk level

110

1.47%CAD 28.29

WELL Health Technologies Corp

WELL Health Technologies Corp Valor: 42769021

Annual Return

-50%0%+50%

Risk level

110

-0.70%CAD 4.25

SIX

FactSet

Clearbit

Logos provided by Clearbit